The innovation—a handheld dry powder inhaler for newborns in respiratory distress—recently cleared a proof-of-concept ...

Neonates with an EGA of >29 weeks who required surfactant treatment because of respiratory distress syndrome (RDS) were also enrolled. The prophylaxis group included all neonates with an EGA of ...

The division currently has 26 faculty members. Clinical research interests of our faculty include: respiratory distress syndrome, neonatal infections and immunology, persistent pulmonary hypertension, ...

They did not specifically exclude all infants without RDS, such as those with meconium ... arises in prophylactic use in our preterm neonates. Although both surfactants remain on the formulary ...